Published in J Clin Invest on August 22, 2016
Tie1 controls angiopoietin function in vascular remodeling and inflammation. J Clin Invest (2016) 0.81
Structural basis of Tie2 activation and Tie2/Tie1 heterodimerization. Proc Natl Acad Sci U S A (2017) 0.77
Plastic roles of pericytes in the blood-retinal barrier. Nat Commun (2017) 0.76
Dimerization of Tie2 mediated by its membrane-proximal FNIII domains. Proc Natl Acad Sci U S A (2017) 0.76
Sustained inflammation after pericyte depletion induces irreversible blood-retina barrier breakdown. JCI Insight (2017) 0.75
Angiopoietin-2 in white adipose tissue improves metabolic homeostasis through enhanced angiogenesis. Elife (2017) 0.75
Angiopoietin-Tie signalling in the cardiovascular and lymphatic systems. Clin Sci (Lond) (2017) 0.75
Tie1: an orphan receptor provides context for angiopoietin-2/Tie2 signaling. J Clin Invest (2016) 0.75
Low Serum Angiopoietin-1, High Serum Angiopoietin-2, and High Ang-2/Ang-1 Protein Ratio are Associated with Early Onset Sepsis in Surinamese Newborns. Shock (2017) 0.75
Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell (1999) 32.32
A gene expression atlas of the central nervous system based on bacterial artificial chromosomes. Nature (2003) 16.48
Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science (1997) 15.48
Vascular-specific growth factors and blood vessel formation. Nature (2000) 14.42
Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis. Cell (1996) 13.95
Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science (1999) 9.18
Distinct roles of the receptor tyrosine kinases Tie-1 and Tie-2 in blood vessel formation. Nature (1995) 8.12
Leakage-resistant blood vessels in mice transgenically overexpressing angiopoietin-1. Science (1999) 6.96
Angiopoietin-2 is required for postnatal angiogenesis and lymphatic patterning, and only the latter role is rescued by Angiopoietin-1. Dev Cell (2002) 6.41
Angiopoietin-1 protects the adult vasculature against plasma leakage. Nat Med (2000) 5.58
Control of vascular morphogenesis and homeostasis through the angiopoietin-Tie system. Nat Rev Mol Cell Biol (2009) 5.55
Angiopoietin-2 sensitizes endothelial cells to TNF-alpha and has a crucial role in the induction of inflammation. Nat Med (2006) 5.49
Vascular dysmorphogenesis caused by an activating mutation in the receptor tyrosine kinase TIE2. Cell (1996) 5.10
Angiopoietin-1 regulates endothelial cell survival through the phosphatidylinositol 3'-Kinase/Akt signal transduction pathway. Circ Res (2000) 4.97
Excess circulating angiopoietin-2 may contribute to pulmonary vascular leak in sepsis in humans. PLoS Med (2006) 3.72
Increased vascularization in mice overexpressing angiopoietin-1. Science (1998) 3.67
Involvement of Foxo transcription factors in angiogenesis and postnatal neovascularization. J Clin Invest (2005) 3.66
Vascular endothelial growth factor (VEGF) induces remodeling and enhances TH2-mediated sensitization and inflammation in the lung. Nat Med (2004) 3.64
The Tie-2 ligand angiopoietin-2 is stored in and rapidly released upon stimulation from endothelial cell Weibel-Palade bodies. Blood (2004) 3.50
Angiopoietin-1 inhibits endothelial cell apoptosis via the Akt/survivin pathway. J Biol Chem (2000) 3.30
The receptor tyrosine kinase TIE is required for integrity and survival of vascular endothelial cells. EMBO J (1995) 3.16
Endothelial adherens junctions control tight junctions by VE-cadherin-mediated upregulation of claudin-5. Nat Cell Biol (2008) 3.15
Angiopoietins assemble distinct Tie2 signalling complexes in endothelial cell-cell and cell-matrix contacts. Nat Cell Biol (2008) 2.85
Abnormal angiogenesis in Foxo1 (Fkhr)-deficient mice. J Biol Chem (2004) 2.73
Tie2 expression and phosphorylation in angiogenic and quiescent adult tissues. Circ Res (1997) 2.58
Differential function of Tie2 at cell-cell contacts and cell-substratum contacts regulated by angiopoietin-1. Nat Cell Biol (2008) 2.35
The Tie-2 ligand angiopoietin-2 destabilizes quiescent endothelium through an internal autocrine loop mechanism. J Cell Sci (2005) 2.35
Phosphorylation of serine 256 suppresses transactivation by FKHR (FOXO1) by multiple mechanisms. Direct and indirect effects on nuclear/cytoplasmic shuttling and DNA binding. J Biol Chem (2002) 2.33
Angiopoietin-1 modulates endothelial cell function and gene expression via the transcription factor FKHR (FOXO1). Genes Dev (2004) 2.32
Angiopoietin-2 at high concentration can enhance endothelial cell survival through the phosphatidylinositol 3'-kinase/Akt signal transduction pathway. Oncogene (2000) 2.32
Tyrosine 1101 of Tie2 is the major site of association of p85 and is required for activation of phosphatidylinositol 3-kinase and Akt. Mol Cell Biol (1998) 2.28
Long-term and sustained COMP-Ang1 induces long-lasting vascular enlargement and enhanced blood flow. Circ Res (2005) 2.14
Angiopoietin 2 is a partial agonist/antagonist of Tie2 signaling in the endothelium. Mol Cell Biol (2009) 2.09
Angiopoietin-2 functions as an autocrine protective factor in stressed endothelial cells. Proc Natl Acad Sci U S A (2006) 2.03
Biological action of angiopoietin-2 in a fibrin matrix model of angiogenesis is associated with activation of Tie2. Cardiovasc Res (2001) 1.95
Angiopoietin-2 differentially regulates angiogenesis through TIE2 and integrin signaling. J Clin Invest (2012) 1.85
COMP-Ang1: a designed angiopoietin-1 variant with nonleaky angiogenic activity. Proc Natl Acad Sci U S A (2004) 1.85
Endothelial gaps and permeability of venules in rat tracheas exposed to inflammatory stimuli. Am J Physiol (1994) 1.77
TNF-alpha drives remodeling of blood vessels and lymphatics in sustained airway inflammation in mice. J Clin Invest (2009) 1.76
Angiogenesis in mice with chronic airway inflammation: strain-dependent differences. Am J Pathol (1998) 1.69
Time course of endothelial cell proliferation and microvascular remodeling in chronic inflammation. Am J Pathol (2001) 1.67
Angiopoietins have distinct modular domains essential for receptor binding, dimerization and superclustering. Nat Struct Biol (2003) 1.63
Identification of Tek/Tie2 binding partners. Binding to a multifunctional docking site mediates cell survival and migration. J Biol Chem (1999) 1.60
Angiopoietin-2 causes pericyte dropout in the normal retina: evidence for involvement in diabetic retinopathy. Diabetes (2004) 1.59
Defective remodeling and maturation of the lymphatic vasculature in Angiopoietin-2 deficient mice. Dev Biol (2008) 1.52
Angiopoietin-2 plays an important role in retinal angiogenesis. J Cell Physiol (2002) 1.50
Angiopoietin-2 functions as a Tie2 agonist in tumor models, where it limits the effects of VEGF inhibition. Cancer Res (2012) 1.50
Age-related changes in vascular endothelial growth factor dependency and angiopoietin-1-induced plasticity of adult blood vessels. Circ Res (2004) 1.45
A human monoclonal anti-ANG2 antibody leads to broad antitumor activity in combination with VEGF inhibitors and chemotherapy agents in preclinical models. Mol Cancer Ther (2010) 1.45
Regulated angiogenesis and vascular regression in mice overexpressing vascular endothelial growth factor in airways. Am J Pathol (2004) 1.39
Chronic respiratory mycoplasmosis in C3H/HeN and C57BL/6N mice: lesion severity and antibody response. Infect Immun (1995) 1.36
Angiopoietin 2 mediates microvascular and hemodynamic alterations in sepsis. J Clin Invest (2013) 1.32
Angiopoietin-2 impairs revascularization after limb ischemia. Circ Res (2007) 1.29
Contact inhibition (of proliferation) redux. Curr Opin Cell Biol (2012) 1.22
Activation of Tie2 by angiopoietin-1 and angiopoietin-2 results in their release and receptor internalization. J Cell Sci (2006) 1.17
In vivo actions of angiopoietins on quiescent and remodeling blood and lymphatic vessels in mouse airways and skin. Arterioscler Thromb Vasc Biol (2006) 1.15
Angiopoietin 1 is mitogenic for cultured endothelial cells. Cancer Res (2005) 1.15
Conditional transgene expression in endothelial cells. Transgenic Res (1998) 1.12
Endothelial destabilization by angiopoietin-2 via integrin β1 activation. Nat Commun (2015) 1.09
Pericyte requirement for anti-leak action of angiopoietin-1 and vascular remodeling in sustained inflammation. Am J Pathol (2011) 1.08
Angiopoietin-2-driven vascular remodeling in airway inflammation. Am J Pathol (2010) 1.07
Complementary and coordinated roles of the VEGFs and angiopoietins during normal and pathologic vascular formation. Cold Spring Harb Symp Quant Biol (2002) 1.05
Abnormal recruitment of periendothelial cells to lymphatic capillaries in digestive organs of angiopoietin-2-deficient mice. Cell Tissue Res (2007) 1.03
Angiopoietin-1 guides directional angiogenesis through integrin αvβ5 signaling for recovery of ischemic retinopathy. Sci Transl Med (2013) 1.02
Activity of the pan-class I phosphoinositide 3-kinase inhibitor NVP-BKM120 in T-cell acute lymphoblastic leukemia. Leukemia (2013) 1.00
Targeting VE-PTP activates TIE2 and stabilizes the ocular vasculature. J Clin Invest (2014) 0.99
Angiopoietin-2 is critical for cytokine-induced vascular leakage. PLoS One (2013) 0.99
Yes-associated protein regulates endothelial cell contact-mediated expression of angiopoietin-2. Nat Commun (2015) 0.98
Chronic systemic delivery of angiopoietin-2 reveals a possible independent angiogenic effect. Am J Physiol Heart Circ Physiol (2006) 0.94
Dysmorphogenesis of kidney cortical peritubular capillaries in angiopoietin-2-deficient mice. Am J Pathol (2004) 0.89
Angiopoietin/Tie2 signaling transforms capillaries into venules primed for leukocyte trafficking in airway inflammation. Am J Pathol (2010) 0.88
Rapamycin improves TIE2-mutated venous malformation in murine model and human subjects. J Clin Invest (2015) 0.87
The molecular balance between receptor tyrosine kinases Tie1 and Tie2 is dynamically controlled by VEGF and TNFα and regulates angiopoietin signalling. PLoS One (2012) 0.86
Tie1 controls angiopoietin function in vascular remodeling and inflammation. J Clin Invest (2016) 0.81
Synergistic Actions of Blocking Angiopoietin-2 and Tumor Necrosis Factor-α in Suppressing Remodeling of Blood Vessels and Lymphatics in Airway Inflammation. Am J Pathol (2015) 0.77
VEGF guides angiogenic sprouting utilizing endothelial tip cell filopodia. J Cell Biol (2003) 12.96
Copy number variation and selection during reprogramming to pluripotency. Nature (2011) 8.24
Molecular regulation of angiogenesis and lymphangiogenesis. Nat Rev Mol Cell Biol (2007) 7.75
Vascular endothelial growth factor C is required for sprouting of the first lymphatic vessels from embryonic veins. Nat Immunol (2003) 7.42
Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis. Nature (2006) 7.01
Binding of ras to phosphoinositide 3-kinase p110alpha is required for ras-driven tumorigenesis in mice. Cell (2007) 6.44
Angiopoietin-2 is required for postnatal angiogenesis and lymphatic patterning, and only the latter role is rescued by Angiopoietin-1. Dev Cell (2002) 6.41
Rapid vascular regrowth in tumors after reversal of VEGF inhibition. J Clin Invest (2006) 6.12
CD133 expression is not restricted to stem cells, and both CD133+ and CD133- metastatic colon cancer cells initiate tumors. J Clin Invest (2008) 5.96
Lymphangiogenesis: Molecular mechanisms and future promise. Cell (2010) 5.84
VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature. Am J Physiol Heart Circ Physiol (2005) 5.56
Control of vascular morphogenesis and homeostasis through the angiopoietin-Tie system. Nat Rev Mol Cell Biol (2009) 5.55
Angiopoietin-2 sensitizes endothelial cells to TNF-alpha and has a crucial role in the induction of inflammation. Nat Med (2006) 5.49
Blocking VEGFR-3 suppresses angiogenic sprouting and vascular network formation. Nature (2008) 5.15
Abnormalities in pericytes on blood vessels and endothelial sprouts in tumors. Am J Pathol (2002) 5.04
Tumor-associated macrophages express lymphatic endothelial growth factors and are related to peritumoral lymphangiogenesis. Am J Pathol (2002) 4.66
Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts. Am J Pathol (2004) 4.47
Functionally specialized junctions between endothelial cells of lymphatic vessels. J Exp Med (2007) 4.10
Pathogenesis of persistent lymphatic vessel hyperplasia in chronic airway inflammation. J Clin Invest (2005) 4.09
Macrophages regulate salt-dependent volume and blood pressure by a vascular endothelial growth factor-C-dependent buffering mechanism. Nat Med (2009) 4.07
Haploinsufficiency of delta-like 4 ligand results in embryonic lethality due to major defects in arterial and vascular development. Proc Natl Acad Sci U S A (2004) 4.06
Lymphatic endothelial reprogramming of vascular endothelial cells by the Prox-1 homeobox transcription factor. EMBO J (2002) 3.99
Lymphangiogenesis and cancer metastasis. Nat Rev Cancer (2002) 3.90
Vascular endothelial growth factor (VEGF) induces remodeling and enhances TH2-mediated sensitization and inflammation in the lung. Nat Med (2004) 3.64
Endothelial cells dynamically compete for the tip cell position during angiogenic sprouting. Nat Cell Biol (2010) 3.61
Microenvironmental VEGF concentration, not total dose, determines a threshold between normal and aberrant angiogenesis. J Clin Invest (2004) 3.53
The Tie-2 ligand angiopoietin-2 is stored in and rapidly released upon stimulation from endothelial cell Weibel-Palade bodies. Blood (2004) 3.50
Suppression of tumor lymphangiogenesis and lymph node metastasis by blocking vascular endothelial growth factor receptor 3 signaling. J Natl Cancer Inst (2002) 3.44
Cellular abnormalities of blood vessels as targets in cancer. Curr Opin Genet Dev (2005) 3.38
Kaposi sarcoma herpesvirus-induced cellular reprogramming contributes to the lymphatic endothelial gene expression in Kaposi sarcoma. Nat Genet (2004) 3.38
Defective valves and abnormal mural cell recruitment underlie lymphatic vascular failure in lymphedema distichiasis. Nat Med (2004) 3.32
PDZ interaction site in ephrinB2 is required for the remodeling of lymphatic vasculature. Genes Dev (2005) 3.29
VEGFs and receptors involved in angiogenesis versus lymphangiogenesis. Curr Opin Cell Biol (2009) 3.28
Cellular changes in normal blood capillaries undergoing regression after inhibition of VEGF signaling. Am J Physiol Heart Circ Physiol (2005) 3.28
Bone marrow-derived circulating endothelial precursors do not contribute to vascular endothelium and are not needed for tumor growth. Proc Natl Acad Sci U S A (2008) 3.27
The biology of vascular endothelial growth factors. Cardiovasc Res (2005) 3.22
Endothelial adherens junctions control tight junctions by VE-cadherin-mediated upregulation of claudin-5. Nat Cell Biol (2008) 3.15
Vascular endothelial growth factor ligands and receptors that regulate human cytotrophoblast survival are dysregulated in severe preeclampsia and hemolysis, elevated liver enzymes, and low platelets syndrome. Am J Pathol (2002) 2.99
Adult bone marrow-derived cells recruited during angiogenesis comprise precursors for periendothelial vascular mural cells. Blood (2004) 2.95
Lymphatic endothelial cell identity is reversible and its maintenance requires Prox1 activity. Genes Dev (2008) 2.91
Angiopoietins assemble distinct Tie2 signalling complexes in endothelial cell-cell and cell-matrix contacts. Nat Cell Biol (2008) 2.85
Abnormal lymphatic vessel development in neuropilin 2 mutant mice. Development (2002) 2.68
VEGF-C-induced lymphangiogenesis in sentinel lymph nodes promotes tumor metastasis to distant sites. Blood (2006) 2.66
Suppression of tumor invasion and metastasis by concurrent inhibition of c-Met and VEGF signaling in pancreatic neuroendocrine tumors. Cancer Discov (2012) 2.57
VEGFR-3 and CD133 identify a population of CD34+ lymphatic/vascular endothelial precursor cells. Blood (2002) 2.52
Molecular biology and pathology of lymphangiogenesis. Annu Rev Pathol (2008) 2.49
Vascular endothelial cell growth factor receptor 3-mediated activation of lymphatic endothelium is crucial for tumor cell entry and spread via lymphatic vessels. Cancer Res (2005) 2.48
Macrophage skewing by Phd2 haplodeficiency prevents ischaemia by inducing arteriogenesis. Nature (2011) 2.47
Significance of blood vessel leakiness in cancer. Cancer Res (2002) 2.43
VEGF and angiopoietin signaling in tumor angiogenesis and metastasis. Trends Mol Med (2011) 2.38
Abnormalities of basement membrane on blood vessels and endothelial sprouts in tumors. Am J Pathol (2003) 2.37
Resident physicians' preparedness to provide cross-cultural care. JAMA (2005) 2.36
Angiopoietin-1 decreases plasma leakage by reducing number and size of endothelial gaps in venules. Am J Physiol Heart Circ Physiol (2005) 2.34
Lymphatic endothelial cell sphingosine kinase activity is required for lymphocyte egress and lymphatic patterning. J Exp Med (2009) 2.34
Signaling and functions of angiopoietin-1 in vascular protection. Circ Res (2006) 2.34
Critical role of CD11b+ macrophages and VEGF in inflammatory lymphangiogenesis, antigen clearance, and inflammation resolution. Blood (2009) 2.30
Blockade of vascular endothelial growth factor receptor-3 signaling inhibits fibroblast growth factor-2-induced lymphangiogenesis in mouse cornea. Proc Natl Acad Sci U S A (2002) 2.30
Therapeutic differentiation and maturation of lymphatic vessels after lymph node dissection and transplantation. Nat Med (2007) 2.29
VEGF-D is the strongest angiogenic and lymphangiogenic effector among VEGFs delivered into skeletal muscle via adenoviruses. Circ Res (2003) 2.25
VEGF Trap complex formation measures production rates of VEGF, providing a biomarker for predicting efficacious angiogenic blockade. Proc Natl Acad Sci U S A (2007) 2.19
The Janus kinases (Jaks). Genome Biol (2004) 2.18
FOXC2 controls formation and maturation of lymphatic collecting vessels through cooperation with NFATc1. J Cell Biol (2009) 2.17
Nrarp coordinates endothelial Notch and Wnt signaling to control vessel density in angiogenesis. Dev Cell (2009) 2.17
Overexpression of vascular endothelial growth factor-B in mouse heart alters cardiac lipid metabolism and induces myocardial hypertrophy. Circ Res (2008) 2.15
Long-term and sustained COMP-Ang1 induces long-lasting vascular enlargement and enhanced blood flow. Circ Res (2005) 2.14
Lymphatic vasculature: development, molecular regulation and role in tumor metastasis and inflammation. Trends Immunol (2004) 2.13
Use of cancer-specific genomic rearrangements to quantify disease burden in plasma from patients with solid tumors. Genes Chromosomes Cancer (2010) 2.11
VEGFR-3 controls tip to stalk conversion at vessel fusion sites by reinforcing Notch signalling. Nat Cell Biol (2011) 2.09
Novel function for blood platelets and podoplanin in developmental separation of blood and lymphatic circulation. Blood (2010) 2.04
Angiopoietin-2 functions as an autocrine protective factor in stressed endothelial cells. Proc Natl Acad Sci U S A (2006) 2.03
Global lymphoid tissue remodeling during a viral infection is orchestrated by a B cell-lymphotoxin-dependent pathway. Blood (2010) 2.03
Neural guidance molecules regulate vascular remodeling and vessel navigation. Genes Dev (2005) 2.01
VEGF and c-Met blockade amplify angiogenesis inhibition in pancreatic islet cancer. Cancer Res (2011) 1.92
Regulation of Jak2 through the ubiquitin-proteasome pathway involves phosphorylation of Jak2 on Y1007 and interaction with SOCS-1. Mol Cell Biol (2002) 1.92
Immune cells control skin lymphatic electrolyte homeostasis and blood pressure. J Clin Invest (2013) 1.92
The lymphatic vasculature: recent progress and paradigms. Annu Rev Cell Dev Biol (2005) 1.91
Complementary actions of inhibitors of angiopoietin-2 and VEGF on tumor angiogenesis and growth. Cancer Res (2010) 1.90
Lipoxygenase mediates invasion of intrametastatic lymphatic vessels and propagates lymph node metastasis of human mammary carcinoma xenografts in mouse. J Clin Invest (2011) 1.88
Reevaluation of the role of VEGF-B suggests a restricted role in the revascularization of the ischemic myocardium. Arterioscler Thromb Vasc Biol (2008) 1.88
Contrasting actions of selective inhibitors of angiopoietin-1 and angiopoietin-2 on the normalization of tumor blood vessels. Am J Pathol (2009) 1.87
Biological basis of therapeutic lymphangiogenesis. Circulation (2011) 1.85
Vascular growth factors and lymphangiogenesis. Physiol Rev (2002) 1.85